Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| vTv Therapeutics Inc.VTVT · Entity 6614 | EVP & CFO | February 17, 2026 | February 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
vTv Therapeutics Inc.
Report date February 17, 2026 · Filed February 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.92 · Expires 2036-02-17 | Direct | 89,969 |
Reported balance
After 2026-02-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-17 · Grant · Acquired 44,969 · Balance 89,969 F1: The options vest 25% on the first anniversary of the grant date and in quarterly equal installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest 25% on the first anniversary of the grant date and in quarterly equal installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 17, 2026 Filed Feb 18, 2026 21:11 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | GrantEmployee stock option (right to buy) · Derivative | 44,969 | $36.92 Strike: $36.92 | $1,660,255.48 |
DisclosureSEC source: 0002069755-26-000003 · wk-form4_1771449065.xml · derivative · entry 1 Tung Michael Stephen · CIK 0002069755 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,969 Underlying: Class A Common Stock · 44,969 shares Expires 2036-02-17 F1 · derivative.exercise_date: The options vest 25% on the first anniversary of the grant date and in quarterly equal installments thereafter. Read SEC document |
| May 19, 2025 Filed May 21, 2025 22:17 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | GrantEmployee stock option (right to buy) · Derivative | 45,000 | $21.25 Strike: $21.25 | $956,250.00 |
DisclosureSEC source: 0001641489-25-000036 · wk-form4_1747865835.xml · derivative · entry 1 Tung Michael Stephen · CIK 0002069755 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Class A Common Stock · 45,000 shares Expires 2035-05-19 F1 · derivative.exercise_date: Vests 25% on the 1st anniversary of the grant and the remaining vest quarterly over three years, subject to continued employment. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.